| scholarly article | Q13442814 |
| P2093 | author name string | Nguyen T | |
| Mano T | |||
| Walsh K | |||
| Smith RC | |||
| Wills KN | |||
| Gregory RJ | |||
| Antelman D | |||
| Avanzini JB | |||
| P2860 | cites work | Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells | Q27860607 |
| Transcriptional regulatory elements in the 5' upstream and first intron regions of the human smooth muscle (aortic type) alpha-actin-encoding gene | Q28275740 | ||
| Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria | Q29616614 | ||
| Regulation of smooth muscle alpha-actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions | Q30303899 | ||
| The smooth muscle alpha-actin gene promoter is differentially regulated in smooth muscle versus non-smooth muscle cells | Q30464808 | ||
| A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites | Q33706825 | ||
| Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression | Q36685714 | ||
| Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. | Q37371503 | ||
| Adenoviruses as gene-delivery vehicles | Q40970776 | ||
| Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer | Q41445691 | ||
| Retinoblastoma protein monoclonal antibodies with novel characteristics | Q41481372 | ||
| Retinoblastoma protein switches the E2F site from positive to negative element | Q41613404 | ||
| Identification of a growth suppression domain within the retinoblastoma gene product | Q41619792 | ||
| Smooth muscle cell outgrowth from human atherosclerotic plaque: implications for the assessment of lesion biology | Q42049843 | ||
| Two proximal CArG elements regulate SM alpha-actin promoter, a genetic marker of activated phenotype of mesangial cells | Q42485266 | ||
| Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members | Q44269566 | ||
| Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product | Q45869776 | ||
| Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types | Q45888027 | ||
| Engineered mutants of pRB with improved growth suppression potential | Q46867316 | ||
| Analysis of adenoviral transport mechanisms in the vessel wall and optimization of gene transfer using local delivery catheters | Q64380966 | ||
| Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation | Q64382296 | ||
| Histopathology of in-stent restenosis in patients with peripheral artery disease | Q73303005 | ||
| P433 | issue | 24 | |
| P304 | page(s) | 1847-1854 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle alpha-actin promoter suppresses smooth muscle cell proliferation and neointima formation | |
| P478 | volume | 8 |
| Q37409025 | Adenoviral vector-based strategies for cancer therapy |
| Q35814460 | Development of pro-angiogenic engineered transcription factors for the treatment of cardiovascular disease |
| Q35105875 | Gene Transfer Strategies to Inhibit Neointima Formation |
| Q35648549 | Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. |
| Q37511128 | Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis |
| Q28220309 | Nanoparticulate carriers for the treatment of coronary restenosis |
| Q40770884 | Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy |
| Q35164884 | Targeting the cell cycle machinery for the treatment of cardiovascular disease. |
Search more.